Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Examination of genome-wide methylation changes in lung cancer cell lines A549 (A) and HTB56 (H) [RRBS-Seq experiments]


ABSTRACT: Cancer cell phenotypes are partially determined by epigenetic specifications such as DNA methylation. Metastasis development is a late event in cancerogenesis and might be associated with epigenetic alterations. Here, we analyzed genome wide DNA methylation changes that were associated with pro-metastatic phenotypes in non-small cell lung cancer with Reduced Representation Bisulfite Sequencing. DNMT-inhibition by 5-Azacytidine at low concentrations reverted the pro-metastatic phenotype. 5-Azacytidine led to preferential loss of DNA methylation at sites that were DNA hypermethylated during the in vivo selection. Changes in DNA methylation persisted over time. Keywords: Methylation profiling by high throughput sequencing We studied genome-wide methylation changes in lung cancer cell lines A549 (A) and HTB56 (H). We generated NSCLC lines with highly increased propensity to form tumor nodules in murine lungs after intravenous injections. In addition to the normal cell lines (0R) we analyzed the methylome of the the cell lines after three rounds of in vivo selection towards a highly metastatic phenotype (3R). Next we studied changes in the methylome of highly metastatic cell lines after DNA Methyltransferase inhibition by 5-Azacytidine treatment at low concentrations (250 nM & 1000 nM) for 6 days. During treatment cells were supplemented with fresh medium every 48 hours. After 6 days of 5-Azacytidine exposure, cells were washed three times with PBS to wash out the drug. The cells were released for additional 7 days in regular medium. We followed up the DNA methylation changes at day 13 of the experiment.

ORGANISM(S): Homo sapiens

SUBMITTER: Christian Rohde 

PROVIDER: E-GEOD-52140 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

altmetric image

Publications

DNA methyltransferase inhibition reverses epigenetically embedded phenotypes in lung cancer preferentially affecting polycomb target genes.

Hascher Antje A   Haase Ann-Kristin AK   Hebestreit Katja K   Rohde Christian C   Klein Hans-Ulrich HU   Rius Maria M   Jungen Dominik D   Witten Anika A   Stoll Monika M   Schulze Isabell I   Ogawa Seishi S   Wiewrodt Rainer R   Tickenbrock Lara L   Berdel Wolfgang E WE   Dugas Martin M   Thoennissen Nils H NH   Müller-Tidow Carsten C  

Clinical cancer research : an official journal of the American Association for Cancer Research 20131213 4


<h4>Purpose</h4>Cancer cell phenotypes are partially determined by epigenetic specifications, such as DNA methylation. Metastasis development is a late event in cancerogenesis and might be associated with epigenetic alterations.<h4>Experimental design</h4>An in vivo selection approach was used to generate highly aggressive non-small cell lung cancer (NSCLC) cell lines (A549 and HTB56) followed by genome-wide DNA methylation analysis. Furthermore, the therapeutic effects of the epigenetic agent a  ...[more]

Similar Datasets

2013-12-18 | E-GEOD-44390 | biostudies-arrayexpress
2013-12-18 | E-GEOD-52144 | biostudies-arrayexpress
2013-12-18 | GSE44390 | GEO
2013-12-18 | GSE52140 | GEO
2022-09-27 | GSE190320 | GEO
2009-10-01 | E-GEOD-8374 | biostudies-arrayexpress
2019-05-18 | GSE114665 | GEO
2010-11-15 | E-GEOD-25346 | biostudies-arrayexpress
2013-05-20 | E-GEOD-44075 | biostudies-arrayexpress
2010-04-09 | E-GEOD-20598 | biostudies-arrayexpress